TABLE 1

Anticancer activity of oxaliplatin, KP1537, and KP1691

IC₅₀ values of diverse cell models and resistant sublines after 72 h, calculated from at least three independent dose-response curves.

Cell Line	Oxaliplatin		KP1537		KP1691
Cell Line	IC₅₀	RF	IC₅₀	RF	IC₅₀	RF
	μM		μM		μM
MDA-MB-231	0.8 ± 0.3		1.2 ± 0.8		0.5 ± 0
KB 3-1	1.5 ± 1.2		1.6 ± 1.1		0.6 ± 0.2
A2780	0.4 ± 0.2		0.4 ± 0		0.3 ± 0.1
K-562-S	1.3 ± 1		1.1 ± 0.1		0.6 ± 0.2
HL-60	0.6 ± 0.2		0.7 ± 0.3		0.3 ± 0.1
L1210^{^a}	0.6 ± 0.1		0.6 ± 0.4		0.6 ± 0.1
RPMI-8226	0.5 ± 0.2		0.5 ± 0.3		0.4 ± 0.2
GLC-4	0.8 ± 0.3		0.8 ± 0.1		0.3 ± 0.2
A549	11.5 ± 3.9		7.5 ± 0.6		3.9 ± 2.3
HCT-116 p21(+/+)	1.7 ± 0.4		2.8 ± 0.8		0.6 ± 0.1
HCT-116 p21(−/−)	2.7 ± 0.2	1.5	3.2 ± 0.3	1.2	1 ± 0.1	1.7
HCT-116 bax(+/+)	0.9 ± 0		1.8 ± 0.5		0.6 ± 0.1
HCT-116 bax(−/−)	1.4 ± 0.5	1.6	1.9 ± 0.9	1	0.7 ± 0.1	1.2
HCT-116 p53(+/+)	1.2 ± 0.5		2.3 ± 0.4		1 ± 0.5
HCT-116 p53(−/−)	3.7 ± 1.2	3.1	5.3 ± 1.7	2.3	1.7 ± 1.2	1.7
SW480	0.9 ± 0.3		1.5 ± 0.1		1.2 ± 0.5
CT-26^{^a}	2.4 ± 0.5		4.9 ± 0.3		2.1 ± 0.4
Mean	1.9		2.2		1.0